Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue

Journal of Medicinal Chemistry

Volumn 42, Issue 22, 1999, Pages 4563-4571

  Prokai, Laszlo ^a   Prokai Tatrai, Katalin ^a   Ouyang, Xudong ^a   Kim, Ho Seung ^a   Wu, Whei Mei ^a   Zharikova, Alevtina ^a   Bodor, Nicholas ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; HORMONE ANALOG; PROTIRELIN;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; LIPID SOLUBILITY; MOUSE; NONHUMAN; OXIDATION;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG DESIGN; MICE; PRODRUGS; PYRROLIDONECARBOXYLIC ACID; THYROTROPIN-RELEASING HORMONE;

EID: 0033523943     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980526i     Document Type: Article

References (55)

1. (a) Prokai, L. Delivery of peptides into the central nervous system. Drug Discovery Today 1996, 1, 161-167.
2. (b) Prokai, L. Peptide delivery into the central nervous system: invasive, physiological and chemical approaches. Exp. Opin. Ther. Patents 1997, 7, 233-245.
3. (c) Prokai, L. Peptide drug delivery into the central nervous system. In Progress in Drug Research; Jucker, E. M., Ed.; Birkhäuser: Basel, 1998; Vol. 51, pp 95-131.
4. (a) Brownless, J.; Williams, C. H. Peptidase, peptides, and the mammalian blood-brain barrier. J. Neurochem. 1993, 60, 793-803.
5. (b) Bertler, A.; Falck, B.; Owman, C.; Rosengreen, E. The localisation of monoaminergic blood-brain barrier mechanism. Pharmacol. Rev. 1966, 18, 369-385.
6. Kumar, V.; Banker, G. S. Target-oriented drug delivery systems. In Modern Pharmaceutics, 3rd ed.; Banker, G. S., Rhodes, C. T., Eds.; Marcel Dekker: New York, 1996; p 611.
7. (a) Bodor, N.; Prokai, L.; Wu, W. M.; Farag, H.; Jonalogadda, S.; Kawamura, M.; Simpkins, J. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992, 257, 1698-1670.
8. (b) Prokai-Tatrai, K.; Prokai, L.; Bodor, N. Brain-targeted delivery of a Leu-enkephalin analogue by retrometabolic design. J. Med. Chem. 1996, 39, 4775-4782.
9. 4a which was about 0.3% of the injected dose. An unusual feature of the brain-targeting CDS is that, because of the involvement of oxidation producing membrane-impermeable ("locked-in") compound(s) in the sequential metabolism, blood pharmacokinetics is not of crucial importance for adequate delivery.
10. (a) Bodor, N. Retrometabolic approaches to drug targeting. NIDA Res. Monogr. Ser. 1995, 154, 1-26.
11. (b) Bodor, N. Drug targeting and retrometabolic drug design approaches. Adv. Drug Del. Rev. 1994, 14, 157-166.
12. Chen, P.; Bodor, N.; Wu, W.-M.; Prokai, L. Strategies to target kyotorphin analogues to the brain. J. Med. Chem. 1998, 41, 3773-3781.
13. Schally, A. V.; Bowers, C. Y.; Redding, T. W.; Barrett, J. F. Thyrotropin releasing factor (TRF) from porcine hypothalamus. Biochem. Biophys. Res. Commun. 1966, 25, 165-169.
14. Böler, J.; Enzmann, F.; Folkers, K.; Bowes, C. Y.; Schally, A. V. The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem. Biophys. Res. Commun. 1969, 37, 705-710.
15. Andrews, J. S.; Sahgal, A. The effects of thyrotropin-releasing hormone, metabolites and analogues on locomotor activity in rats. Regul. Pept. 1984, 7, 97-109.
16. Webster, V. A. D.; Griffiths, E. C.; Slater, P. Induction of wetdog shaking in rats by analogues and metabolites of thyrotropin-releasing hormone (TRH). Regul. Pept. 1984, 5, 43-51.
17. Schmidt, D. Effects of thyrotropin releasing hormone (TRH) on pentobarbital-induced decrease in cholinergic neuronal activity. Commun. Psychopharmacol. 1977, 469-473.
18. Horita, A.; Carino, M.; Zabawska, J.; Lai, H. TRH analogue MK-771 reverses neurochemical and learning deficits in medial septal-lesioned rats. Peptides 1989, 10, 121-124.
19. Atweh, S.; Simon, J.; Kuhar, M. Utilization of sodium-dependent high-affinity choline uptake in vitro as a measure of the activity of cholinergic neurons in vivo. Life Sci. 1975, 17, 1535-1544.
20. Itoh, Y.; Ogasawara, T.; Mushiori, A.; Yamazaki, A.; Ukai, Y.; Kimura, K. Effect on NS-3, a thyrotropin-releasing hormone analogue, on in vivo acetylcholine release in rat brain: regional difference and its sites of action. J. Pharmacol. Exp. Ther. 1994, 271, 884-890.
21. Santori, E.; Schmidt, D. Effects of MK-771, a TRH analogue on pentobarbital-induced alteration of cholinergic parameters in discrete regions of the brain. Regul. Pept. 1980, 1, 69-74.
22. Yarbrough, G. Minireview. Thyrotropin releasing hormone and CNS cholinergic neurons. Life Sci. 1983, 33, 111-118.
23. Faden, A. I.; Vink, R.; McIntosh, T. K. Thyrotropin-releasing hormone and central nervous system trauma. Ann. N. Y. Acad. Sci. 1989, 553, 380-384.
24. Sunderland, A.; Mellow, A.; Cohen, R.; Lawlor, B.; Jill, J.; Newhouse, P.; Cohen, M.; Murphy, D. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Psychopharmacology 1989, 98, 403-407.
25. Lampe, T.; Noms, J.; Risse, S.; Owens-Williams, E.; Keenan, T. Basic mechanisms, diagnosis and therapeutic strategies. In Alzheimer's Disease; Iqbal, K., McLachlan, D. R. C., Winbald, B., Wisniewski, H. M., Eds.; John Wiley and Sons, Ltd.: New York, 1991; p 643.
26. Yamamoto, M.; Shimizu, M. Effects of a new TRH analogue, YM-14673 on the central nervous system. Naunyn-Schmiedebergs Arch. Pharmacol. 1987, 336, 561-565.
27. Friedrichs, E.; Schwertner, E.; Herrling, S.; Gunzler, W.-A.; Ottig, F.; Flohe, L. In Structure and activity of natural peptides; Voelter, W., Weitzel, G., Eds.; Walter de Gruyter: Berlin, Germany, 1981; p 461.
28. Nutt, R. F.; Holly, F. W.; Homnick, C.; Hirschmann, R.; Veber, D. F. Synthesis of thyrotropin-releasing hormone analogues with selective central nervous system effects. J. Med. Chem. 1981, 24, 692-698.
29. Szirtes, T. L.; Kisfaludy, L.; Palosi, E.; Szporny, L. Synthesis of thyrotropin-releasing hormone analogues. 1. Complete dissociation of central nervous system effect from thyrotropin-releasing activity. J. Med. Chem. 1984, 27, 741-745.
30. (a) Zlokovic, B. V.; Segal, M. B.; Begley, D. J.; Davson, H.; Rakic, L. Permeability of the blood-cerebrospinal fluid and the blood-brain barriers to thyrotropin-releasing hormone. Brain Res. 1985, 358, 191-199.
31. (b) Zlokovic, B. V.; Lipovac, M. N.; Begley, D. J.; Davson, H.; Rakic, L. Slow penetration of thyrotropin-releasing hormone across the blood-brain barrier of an in situ perfused guinea pig brain. J. Neurochem. 1988, 51, 252-257.
32. Jackson, I. Controversies in TRH biosynthesis and strategies towards the identification of a TRH precursor. Ann. N. Y. Acad. Sci. 1989, 553, 71-75.
33. Richter, K.; Kawashima, E.; Egger, R.; Kreil, G. Biosynthesis of thyrotropin-releasing hormone in the skin of xenopus laevis: partial sequence of the precursor deduced from cloned cDNA. EMBO J. 1994, 3, 617-621.
34. Docherty, K.; Steiner, D. F. Posttranslational proteolysis in polypeptide hormone biosynthesis. Annu. Rev. Physiol. 1982, 44, 625-638.
35. Gainer, H.; Russell, J.; Loh, Y. The enzymology and intracellular organization of peptide precursor processing: the secretory vesicle hypothesis. Neuroendocrinology 1985, 40, 171-184.
36. (a) Bradbury, A.; Finnie, M.; Smith, D. Mechanism of C-terminal amide formation of pituitary enzyme. Nature 1982, 298, 686-688.
37. (b) Martinez, A.; Treston A. M. Where does amidation take place? Mol. Cell. Endocrinol. 1996, 123, 113-117.
38. Husain, I.; Tate, S. S. Formation of the COOH-terminal amide group of thyrotropin-releasing-factor. FEBS Lett. 1983, 152, 277-281.
39. (a) Fischer, W.; Spiess, J. Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutaminyl peptides. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 3628-3632.
40. (b) Busby, Jr. W. H.; Quackenbush, G. E.; Humm, J.; Youngblood, W.; Kizer, J. S. An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. J. Biol. Chem. 1982, 262, 8532-36.
41. Prokai, L.; Ouyang, X.; Wu, W.-M.; Bodor, N. Chemical delivery system to transport a pyroglutamyl peptide amide to the central nervous system. J. Am. Chem. Soc. 1994, 116, 2643-2644.
42. (a) Eto, Y.; Suzuki, K. Cholesterol ester metabolism in rat brain. A cholesterol ester hydrolase specifically localized in the myelin sheath. J. Biol. Chem. 1973, 248, 1986-1991.
43. (b) Johnson, R. C.; Shah, S. N. Cholesterol ester metabolizing enzymes in human brain: properties, subcellular distribution and releative levels in various diseased conditions. J. Neurochem. 1978, 31, 895-902.
44. Kenny, A. J.; Booth, A. G.; George, S. G.; Ingram, J.; Kershaw, D.; Wood, E. J.; Young, A. R. Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem. J. 1976, 157, 169-182.
45. Walter, R.; Simmons, W. H.; Yosimoto, T. Proline specific endo-and exopeptidase. Mol. Cell Biochem. 1980, 30, 111-127.
46. Rawlings, N. D.; Polgar, L.; Barrett, A. J. A new family of serine-type peptidases related to prolyl oligopeptidase. Biochem. J. 1991, 279, 907-911.
47. Polgar, L. Unusual secondary specificity of prolyl oligopeptidase and the different reactivities of its two forms toward charged substrates. Biochemistry 1992, 31, 7729-7735.
48. Eisner, V.; Kutha, J. The chemistry of dihydropyridine. Chem. Rev. 1972, 72, 1-42.
49. 18O isotopes) allowed us to conclude that the product with the carboxamide-terminus (16a) was in large excess compared to the one with the carboxyterminus upon incubation of 14a in rat brain homogenate, but it was formed in a small proportion in rat plasma and rat liver homogenate. The ratio of the amide (16a, monoisotopic nominal m/z 547) to the acid (m/z 548) after 30 min of incubation in brain homogenate was calculated to be 4.3:1, while the ratio in plasma and liver homogenate after 60 min of incubation was 1:6.3 and 1:6.7, respectively.
50. See Supporting Information (Figure S-2) for details.
51. Yoo, O.; Powell, C.; Argarwal, K. Molecular cloning and nucleotide sequence of full-length of cDNA coding for porcine gastrin. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 1049-1053.
52. Seeburg, P.; Adelman, J. Characterization of cDNA for precursor of human luteinizing hormone releasing hormone. Nature 1984, 311, 666-668.
53. See Supporting Information (Figure S-3) for chromatogram and mass spectra.
54. It has been noted that a significant difference in analeptic activity was obtained between the targeting system containing both Pro and Ala as spacer (13c and 13f). Although this observation could not be rationalized based on our prior knowledge about the affinity of the enzymes possibly involved in the cleavage toward the peptide bonds of the respective substrates, its detailed study was beyond the scope of this paper.
55. Roepstorff, P.; Fohlman, J. Proposal for a common nomenclature for sequence ions in mass-spectra of peptides. Biomed. Mass Spectrom. 1984, 11, 601.